Hesham Gabr, MD
Retina Specialist · Nashville, TNNPI 1215421326
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,850 of the $4,661 with a category attached, or 61.1%. 13 manufacturers reported payments, led by Alcon at 58.6% of the total. Reporting peaked in 2022 at $2,557 and has fallen 72.6% since, to $700 in 2025.
Across 44 payments — averaging $105.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- Regeneron Healthcare Solutions, Inc.$543
- Astellas Pharma US Inc$295
- Eyepoint US, Inc.$232
- Dutch Ophthalmic, USA$217
- Apellis Pharmaceuticals, Inc.$190
- plus $453 from 7 others
What the payments were for
- Travel & lodging$1,81139%
- Food & beverage$2,85061%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 9 | $2,731 |
| Regeneron Healthcare Solutions, Inc. | 8 | $543 |
| Astellas Pharma US Inc | 7 | $295 |
| Eyepoint US, Inc. | 2 | $232 |
| Dutch Ophthalmic, USA | 2 | $217 |
| Apellis Pharmaceuticals, Inc. | 7 | $190 |
| Genentech, Inc. | 1 | $145 |
| Genentech USA, Inc. | 1 | $123 |
| AbbVie | 3 | $56 |
| Alimera Sciences, Inc. | 1 | $47 |
| Cequr Corporation | 1 | $33 |
| ANI Pharmaceuticals, Inc. | 1 | $33 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NGENUITY$277
- VABYSMO$268
- Constellation$251
- YUTIQ$150
- EVA, combined machine$140
- TISSUEBLUE$140
- EYLEA HD$121
- EYLEA$111
How this compares
$4,661 in reported general payments places this provider in the 60th percentile of 58 retina specialist providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 62 | $2,306 |
| Ketorolac Tromethamine | 27 | $349 |
| Ciprofloxacin Hcl | 15 | $193 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $148 |
| Latanoprost | 17 | $107 |
| Brimonidine Tartrate | 17 | $80 |
| Timolol Maleate | 13 | $52 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Nashville
- Carl AwhNashville$1.3M
- Peter SonkinNashville$949K
- Brandon BusbeeNashville$566K
- Eric SchneiderNashville$134K
- David ReichsteinNashville$114K
- Akshay ThomasNashville$108K
- Franco RecchiaNashville$72K
- Everton ArrindellNashville$39K
- Roy WallaceNashville$19K
- Kenneth MoffatNashville$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.